Clinical research is ever-growing, with over 12,000 studies published on light therapy or photobiomodulation for various conditions.โจโจ
Looks like you havenโt added anything yet, letโs get you started!
Continue shopping
100% of profits go back into the clinical research and product development working toward medical approval. Every Neuronic device sold helps move that work forward.
6
Completed Studies
9
Ongoing Studies
7
Planned Studies
110+
Active Research Participants
Note: This section includes Neuronic's peer-reviewed journal articles, published case series, and pre-print manuscripts across the field of photobiomodulation and light therapy.
PublishedRetrospective case series describing two adolescents with complex PANS/PANDAS histories who received 1070 nm transcranial photobiomodulation (tPBM) and swLORETA neurofeedback as part of routine multidisciplinary care.
PublishedThis randomized controlled trial evaluated a nine-month personalized precision medicine program for adults with mild cognitive impairment or early-stage dementia. The program combined lifestyle and medical interventions, including photobiomodulation at most sites using devices such as the Neuronic Neuradiant 1070. Participants showed significantly greater improvements in cognition, memory, executive function, processing speed, and cognitive symptoms compared with standard care.
PublishedThis study evaluated the effects of tPBM on cognitive performance, specifically in tasks involving vigilance and working memory. The research compared active tPBM with sham stimulation during cognitive tasks and observed neurophysiological effects, including changes in processing speed and stress measures. While preliminary due to a small sample, results are interpreted as supporting further exploration of tPBMโs role in augmenting cognition.
PublishedRecurrent depression and anxiety can be resistant to monotherapies, including psychotherapy, eye movement desensitization and reprocessing (EMDR), and selective serotonin reuptake inhibitors (SSRIs). Over a 12-week tPBM protocol, participants reported improvements in sleep quality, irritability, and depression scores, though anxiety outcomes varied across measures. These preliminary findings suggest that tPBM may offer supportive benefits alongside conventional treatments.
PublishedThis study looked at the effects of photobiomodulation (PBM) therapy on long COVID symptoms like chronic fatigue and brain fog. It tested two devices: a helmet (tPBM) and a whole body light bed. Cognitive tests and brain activity measured before and after the therapy showed significant improvements. The findings suggest that PBM intervention, whether for the brain or body, may help treat brain fog in Long COVID patients.
PublishedThis paper develops and validates a brief self-report tool capturing biophysical factors, lifestyle variables, and trait wellbeing that may influence or contextualize tPBM response. It evaluates the batteryโs validity and reliability to support more consistent measurement of participant-level factors in real-world tPBM research.
Case StudyThis case study examines tPBM in Patient M, who has complex multisystem illness, including Postural Orthostatic Tachycardia Syndrome (POTS), Ehlers-Danlos syndrome (EDS) and seizure-like episodes. The report documents progressive improvements in energy, sleep, cognitive function, exercise tolerance, and functional independence following individualized tPBM protocols.
Case StudyClient I.T. was a typical 40-year-old mother and pharmaceutical sales rep living in Vancouver when her life changed dramatically after a car accident in 2019. What seemed like a mild concussion turned into years of navigating brain fog, anxiety, sensory overload, and fatigue.
Case StudyThis case study used a photobiomodulation (PBM) protocol with the Neuradiant 1070 device on a healthy individual, set at 70 Hz for 12 minutes at 75% intensity. Brain activity was then recorded with the NeuroCatchยฎ Platform, which measures amplitude (brain activity strength) and latency (response speed).
White PaperAt Neuronic we have a commitment to being leaders in the field by ensuring our data, devices, and reporting meet the industryโs highest standards of transparency. The following article shares our approach to accurate measurement, the importance of each key metric (total power, irradiance, and peak wavelength), and why clarity matters more than ever.
Note: The studies listed here represent a subset of our ongoing research. Additional studies may not be displayed due to active data collection, publication timelines, or confidentiality requirements
In ProgressThis randomized, sham-controlled pilot trial will evaluate Neuronic tPBM in individuals with mild cognitive impairment (MCI) and early to moderate Alzheimerโs disease. The study will compare active tPBM with sham treatment, assessing preliminary effects on cognition, memory, daily functioning, safety, tolerability, and treatment adherence.
In ProgressInvestigating the Individual and Combined Effects of Photobiomodulation (PBM) and Virtual Reality (VR) Interventions on ADHD Symptoms.
In ProgressThis pilot double-blinded, randomized, placebo-controlled trial compares the effects of pulsed and continuous transcranial photobiomodulation (tPBM) to a placebo in individuals with chronic fatigue. The study aims to assess the efficacy of different tPBM protocols in managing chronic fatigue.
In ProgressNeuronic is partnering with the University of Nottingham to study tPBM's effects on brain hemodynamics using neuroimaging.
In ProgressAt Neuronic, we are conducting internal research to strengthen the scientific foundation of our photobiomodulation (PBM) device and contribute to the growing body of literature on this promising modality. Our work integrates anonymised user data with the scientifically validated PROMIS-10, a standardised tool developed by the NIH to assess global physical and mental health.
